Kennedy Capital Management LLC Invests $1.51 Million in West Pharmaceutical Services, Inc. (NYSE:WST)

Kennedy Capital Management LLC purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,819 shares of the medical instruments supplier’s stock, valued at approximately $1,511,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Pitcairn Co. raised its holdings in West Pharmaceutical Services by 3.4% in the first quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier’s stock worth $346,000 after purchasing an additional 29 shares in the last quarter. Copperwynd Financial LLC grew its holdings in West Pharmaceutical Services by 4.0% in the fourth quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier’s stock worth $274,000 after purchasing an additional 30 shares during the period. Clearbridge Investments LLC increased its stake in shares of West Pharmaceutical Services by 0.7% during the first quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier’s stock valued at $1,779,000 after purchasing an additional 31 shares in the last quarter. RFG Advisory LLC lifted its holdings in shares of West Pharmaceutical Services by 2.3% during the first quarter. RFG Advisory LLC now owns 1,465 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 33 shares during the last quarter. Finally, Peninsula Asset Management Inc. boosted its position in shares of West Pharmaceutical Services by 0.4% in the 4th quarter. Peninsula Asset Management Inc. now owns 9,580 shares of the medical instruments supplier’s stock worth $3,373,000 after purchasing an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Insider Transactions at West Pharmaceutical Services

In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Eric Mark Green sold 66,000 shares of the company’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Company insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $306.17 on Thursday. The business has a fifty day moving average price of $321.68 and a 200-day moving average price of $354.64. The company has a market capitalization of $22.21 billion, a PE ratio of 40.39, a PEG ratio of 10.66 and a beta of 1.00. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $415.73. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.11 EPS. As a group, equities analysts expect that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current fiscal year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.